News & Investment Information

Aug 5, 2013

THE MEDICINES COMPANY ANNOUNCES POSITIVE PHASE III TRIAL RESULTS FOR FIBROCAPS; COMPLETES
PROFIBRIX ACQUISITION

In Phase III trial, FINISH-3, Fibrocaps meets all pre-specified endpoints

MAA filing anticipated in Europe (Q4 2013); BLA filing anticipated in U.S. (Q1 2014)

The Medicines Company builds on existing hemostasis franchise

Parsippany, NJ, Leiden, the Netherlands and Seattle, WA, August 5, 2013— The Medicines Company (NASDAQ: MDCO) announced the results of the pivotal Phase III clinical trial of ProFibrix’s lead biologic, Fibrocaps, a dry
powder topical formulation of fibrinogen and thrombin...

Jun 4, 2013

THE MEDICINES COMPANY SIGNS AGREEMENT TO ACQUIRE PROFIBRIX

Affirms The Medicines Company’s presence in surgical hemostasis

ProFibrix lead product Fibrocaps expected to deliver Phase 3 data third quarter 2013

Highlights The Medicines Company’s long term commitment to recombinant proteins

Parsippany, NJ, Leiden, the Netherlands and Seattle, WA, June 4, 2013— The Medicines Company (NASDAQ: MDCO) and ProFibrix B.V. today announced an agreement for The Medicines Company  to purchase all of the outstanding capital stock of ProFibrix B.V. subject to...

Apr 4, 2013

ProFibrix Completes Patient Enrolment in Pivotal Phase III with FibrocapsTM and Reports Positive Feedback from Surgical Community

Company remains on track for 2013 filings in US and Europe

Leiden, The Netherlands and Seattle, WA, April 4, 2013 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced that the company has completed enrolment of its pivotal Phase III clinical trial...

Feb 13, 2013

ProFibrix Phase III Trial with FibrocapsTM (FINISH-3)
Passes Important Safety Milestone & Almost Completes Enrolment

Leiden, The Netherlands and Seattle, WA, February 13, 2013 - ProFibrix B.V., the leader in next generation hemostatics, today announced that the Data Monitoring Committee (DMC) of the FINISH-3 trial of Fibrocaps unanimously...

Nov 8, 2012

ProFibrix Passes Halfway Mark of Patient Enrolment in Pivotal Phase III with FibrocapsTM and Successfully Concludes Safety Review Assessment

Company firmly on track for 2013 regulatory filings in US and Europe

Leiden, The Netherlands and Seattle, WA, November 8, 2012 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced that the company has enrolled already more than half of the patients in...

Jul 4, 2012

ProFibrix Enrolls First Patients in Pivotal Phase III Study with FibrocapsTM

Lead product on track for market launch in 2014

Leiden, The Netherlands and Seattle, WA, June 6, 2012 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in...

Jul 4, 2012

ProFibrix to Present FibrocapsTM Phase II Data & Progress in Recombinant Fibrinogen Program at International Conferences

Leiden, The Netherlands and Seattle, WA, July 4, 2012 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), will present the results of the company’s Fibrocaps Phase II (FC-002) trial, as well as...

Jan 4, 2012
ProFibrix US Phase II Study with FibrocapsTM Meets All Primary and Secondary Endpoints

Leiden, The Netherlands and Seattle, WA, January 5, 2012 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general...

Nov 15, 2011
ProFibrix Phase II with FibrocapsTM Meets Primary Endpoint – On Track for Phase III in 2012

Leiden, The Netherlands and Seattle, WA, November 15, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted...

Sep 15, 2011
ProFibrix Completes Enrollment of Phase II Studies with Lead Hemostasis Product FibrocapsTM and Targets Start of Phase III in H1 2012

Leiden, The Netherlands and Seattle, WA, September 14, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center...

May 3, 2011
ProFibrix secures funding for progression of lead product into late stage clinical developmentand announces management and supervisory board appointments

Leiden, The Netherlands and Seattle, WA, May 3, 2011 - ProFibrix B.V., a leader in the development of innovative products that help stop bleeding (hemostasis) after surgery, today announced the successful closing of a series B follow-on financing. In conjunction...

Mar 8, 2011
ProFibrix Initiates Phase II with Lead Hemostasis Product FibrocapsTM in US and Europe

Leiden, The Netherlands and Seattle, WA, March 8, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps...

Aug 23, 2010
ProFibrix to Present Phase II Data at International Fibrinogen Workshop in Rotterdam, the Netherlands

Leiden and Rotterdam, The Netherlands, August 23, 2010 - ProFibrix B.V., a leader in the development of innovative products based on the blood clotting protein fibrinogen today presents the first Phase II data for its lead product Fibrocaps™. Fibrocaps is...

Jun 17, 2010
ProFibrix and CSL Behring Enter into Fibrinogen and Thrombin Supply Agreement

Leiden, The Netherlands and Seattle, WA, June 17, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical...

Mar 11, 2010
ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps™ and Appoints New Chief Medical Officera

Leiden, The Netherlands and Seattle, WA, March 11, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat...

Aug 24, 2009
ProFibrix raises US $11 million (EUR 8 million) in series B financing

Leiden, The Netherlands and Seattle, WA, August 24, 2009 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment.  The financing...

Aug 24, 2009
ProFibrix obtains government loan of up to EUR 5 million (~ US$7.4 million) to support clinical development of its lead hemostasis product Fibrocaps™

Leiden, The Netherlands and Seattle, WA, January 7, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted...

Jan 13, 2009
ProFibrix Steps Up Recombinant Fibrinogen Program with PER.C6® License from Crucell

Commercial License to Accelerate Development of New Hemostasis Breakthrough Products

Leiden, The Netherlands, January 13 2009 - ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) for PER.C6®,...

Sep 17, 2008
ProFibrix expands Management team and opens US subsidiary

New COO brings financing and product development experience in the US

Leiden, The Netherlands, September 17 2008: ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, today announced that it has added Jan Ohrstrom,...

Mar 26, 2007
ProFibrix raises up to $ 11 million (€ 8.5 million) Series A financing led by Index Ventures

Leiden, The Netherlands, 26 March 2007. ProFibrix  B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair,  today announced that it has closed a Series A financing raising $ 11 Million . The round was...